- 138 Downloads
Hyaluronic acid is a naturally occurring Polysaccharide with distinct physicochemical properties which underlie its application as a viscoelastic tool in ophthalmological surgery. In cataract surgery the role of hyaluronic acid in facilitating procedures and protecting the corneal endothe-lium is well established. Some benefit has also been gained with the use of hyaluronic acid in penetrating keratoplasty, trabeculectomy, retinal reattachment and trauma surgery, although its efficacy in these indications is less well-defined in the published literature.
In addition to its lubricating and cushioning properties, demonstration of some in vitro anti-inflammatory activity and a possible disease-modifying effect for hyaluronic acid in animals has prompted its investigation as a treatment in Osteoarthritis and, to a much lesser extent, in rheumatoid arthritis. Hyaluronic acid 20mg, as weekly intra-articular injections for 3 to 7 weeks, improved knee pain and joint motion in patients with Osteoarthritis. Although this occurred to a greater degree than with placebo in most comparisons, the effects of hyaluronic acid was similar to those of placebo in the largest trial. In the few available comparisons with other agents, hyaluronic acid appeared equivalent to methylprednisolone 40mg (for 3 weeks) and to a single injection of triamcinolone 40mg. Hyaluronic acid was distinguished from other therapies by providing a sustained effect after treatment discontinuation. Together with its very good tolerability profile, these properties justify further study of hyaluronic acid in patients with Osteoarthritis.
Some limited evidence of improvement in patients with rheumatoid arthritis, and a possible healing effect of hyaluronic acid on tympanic membrane perforations, represent additional areas of interest for future investigation.
In summary, hyaluronic acid is a well-established adjunct to cataract surgery and may prove to be a promising option in the treatment of patients with Osteoarthritis. Its very good tolerability provides further impetus for examination of its potential role in an extended scope of arthritic and ophthalmological indications, and in wound healing.
Physical and Pharmacodynamic Properties, and Rationale for Clinical Use
Hyaluronic acid is a naturally occurring glycosaminoglycan which, by virtue of its viscosity, elasticity and other rheological properties, acts as a lubricating and shock absorbing fluid in joints and as an ocular lubricant. The compound also exerts some mediatory effects on cellular activity (see below). Hyaluronic acid is available in formulations of various molecular weight and concentration.
The physicochemical properties of high molecular weight hyaluronic acid provide the rationale for its use as an adjunct in ophthalmic surgery, in preventing collapse of the anterior chamber and facilitating manipulation of ocular tissues. Additionally, in animal models of cataract surgery in vitro and in vivo, hyaluronic acid 1 to 3% protected corneal endothelium from cell damage caused by synthetic lenses. Although in animal studies hyaluronic acid was both more and less effective than hydroxypropylmethylcellulose 2%, and tended to be less effective than the combination product hyaluronic acid 3%/chondroitin sulphate 4%, in clinical trials hyaluronic acid showed a protective effect at least comparable to these agents. Exogenous hyaluronic acid binds to specific sites on corneal endothelium and inhibits free radical formation after surgical damage, suggesting several mechanisms are responsible for its protective effect on the cornea.
Inflammatory reactions and increases in intraocular pressure following instillation of hyaluronic acid in animals have also occurred in humans undergoing ophthalmological surgery (see Clinical Use and Tolerability).
The rationale for investigating hyaluronic acid as a therapy in patients with rheumatoid or Osteoarthritis rests partly on the premise that supplementation of synovial fluid with exogenous product (viscosupplementation) augments the diminished lubricating and cushioning properties of endogenous substance seen in these diseases. This is supported by significant increases in synovial fluid viscosity and hyaluronic acid concentration or molecular weight seen in some arthritic patients injected with intra-articular hyaluronic acid 1%. Importantly, some anti-inflammatory activity is also apparent for high molecular weight hyaluronic acid (< 5 x 105D), as demonstrated by its inhibitory effects on cellular mediators of inflammation in vitro, and by preliminary evidence of reduced synovial membrane inflammation in a few patients with Osteoarthritis after intra-articular hyaluronic acid 20mg for 5 weeks. Modification of cellular migration by hyaluronic acid may also contribute to its apparent beneficial effects on wound healing and tympanic membrane perforation in animals and humans.
Of great interest is the finding that high molecular weight hyaluronic acid (7.5 to 20 x 105D) appears to have some ability to repair or protect cartilage from the pathophysiological processes of arthritis in animal models, and there is limited evidence suggesting such an effect in small numbers of patients with Osteoarthritis. Whether hyaluronic acid exerts a true disease-modifying effect in humans and animals is controversial and awaits confirmation.
The pharmacokinetics of exogenously administered hyaluronic acid are poorly characterised in humans. Normal circulating serum hyaluronic acid levels are in the range 10 to 100 μg/L. Values are increased several-fold in patients with rheumatoid or Osteoarthritis in whom they correlate with clinical inflammatory signs. Hyaluronic acid is rapidly cleared from the systemic circulation, primarily through uptake by receptors on liver endothelium, and degraded to monosaccharides and their oxidation products. It is not catabolised in the eye to any significant extent, but is biotransformed by the liver after diffusion from the eye into plasma.
The elimination half-life (t1/2β) of hyaluronic acid has been calculated as 2.5 to 5.5 minutes in human plasma. As demonstrated in rabbits, the t1/2β in the eye is correlated with the volume of the formulation, but its relationship to molecular weight is equivocal. The contribution of urinary excretion to the elimination of hyaluronic acid in humans is low (μ1% of total clearance).
Application of hyaluronic acid 1% as a viscoelastic adjunct in cataract surgery is of proven value. Hyaluronic acid 1% permits manipulation of ocular tissues, maintains the anterior chamber and protects corneal endothelium from damage. In the published literature, comparisons of hyaluronic acid formulations have not identified clear differences between products for effects on intraocular pressure or endothelial cell loss, and similar results for these parameters were found for hyaluronic acid 1% when compared with hydroxypropylmethylcellulose 2%. All viscoelastic substances produce transient elevations in intraocular pressure peaking within 6 to 12 hours of injection and tending to normalise within 24 hours. It is generally agreed that these elevations are lessened by postoperative aspiration of the product.
Hyaluronic acid has been of some benefit in facilitating corneal transplantation, and in limited investigations was superior to balanced saline solution. When used as internal tamponade during retinal reattachment, particularly in patients without proliferative retinopathy, hyaluronic acid has yielded a success rate of about 50%; however, this decreases over time. Based on available studies, efficacy of hyaluronic acid is equivocal in preventing collapse of the anterior chamber or choroidal detachment in patients with glaucoma undergoing trabeculectomy. The only prospective trial in such patients demonstrated that hyaluronic acid 1% significantly increased bleb formation and decreased the need for timolol eye drops, compared with no treatment. In trauma surgery, use of hyaluronic acid 1% has improved outcome and facilitated removal of traumatic hyphaema. Additionally, hyaluronic acid has shown some promise in other ophthalmological indications such as dry eye and as a drug delivery vehicle.
In patients with Osteoarthritis, knee pain and joint motion were improved with hyaluronic acid 20mg injected intra-articularly weekly for up to 7 weeks. Benefits were generally greater than with placebo; however, 1 large trial reported as an abstract showed no differences between hyaluronic acid 20mg and placebo. In limited comparisons, efficacy of hyaluronic acid 20mg was similar to that of intra-articular methylprednisolone 40mg weekly for 3 weeks and triamcinolone 40mg as a single dose.
The interesting and consistent finding that improvements seen with hyaluronic acid persisted throughout follow-up periods of 2 months to 1 year after discontinuation of treatment, is potentially advantageous and merits further investigation. Other aspects of the clinical profile of hyaluronic acid worthy of pursuit are the possible additive effects of hyaluronic acid with corti-costeroids in patients with Osteoarthritis, and preliminary evidence of efficacy in a few patients with rheumatoid arthritis. Healing rates of about 50% in patients with tympanic membrane perforations treated with hyaluronic acid otically also require confirmation.
The tolerability of hyaluronic acid 1 % as a viscoelastic tool in ophthalmological surgery is very good. Hyaluronic acid is nonimmunogenic; a mild or moderate inflammatory response occurring in virtually all patients after intraocular injection is likely provoked to some extent by the surgical procedure rather than being solely attributable to the product. Transient elevations in intraocular pressure remain within clinically acceptable levels in the majority of patients. Tolerability profiles appear similar for various formulations of hyaluronic acid and in comparison with hydroxypropylmethylcellulose.
Although less experience has been gained with hyaluronic acid in patients with Osteoarthritis, present evidence indicates the agent is also well tolerated in this population. Pain and/or swelling after intra-articular injection have occurred in up to 37% of patients in clinical trials, but resolved spontaneously. In one well-designed trial the incidence of such local reactions was similar for hyaluronic acid 20mg (37% of patients) and placebo (39%). Long term investigations of up to 1 year have shown no unwanted systemic effects or alterations in standard laboratory tests. Local inflammatory reactions have been observed in about 15 to 20% of patients with ruptured tympanic membranes receiving otic hyaluronic acid formulations.
Dosage and Administration
Hyaluronic acid is administered as an ocular injection in concentrations of 1% or greater. Total volume used is less than 1ml during cataract and other anterior segment surgery, and 2 to 4ml during posterior segment procedures. To minimise risk of postoperative elevated intraocular pressure, aspiration of the product is recommended following the procedure. Patients with rheumatoid or Osteoarthritis have received intra-articular hyaluronic acid 20mg weekly for up to 7 weeks in clinical trials. For healing of tympanic membrane perforations, hyaluronic acid 1% (0.1 to 0.3ml) has been instilled daily for an average of 10 days.
KeywordsHyaluronic Acid Intraocular Pressure Cataract Surgery Sodium Hyaluronate Corneal Endothelium
Unable to display preview. Download preview PDF.
- Abatangelo G, Botti P, Del Bue M, Gei G, Samson JC, et al. Intraarticular sodium hyaluronate injections in the Pond-Nuki experimental model of Osteoarthritis in dogs. Clinical Orthopedics and Related Research 241: 278–285, 1989Google Scholar
- Abatangelo G, Brun P, Cortivo R. The experimental pharmacology of hyaluronic acid (hyaluronan). European Journal of Rheumatology and Inflammation, 1993, in pressGoogle Scholar
- Adams ME. An analysis of clinical studies of the use of crosslinked hyaluronan, hyalan, in the treatment of Osteoarthritis. Journal of Rheumatology 20 (Suppl. 39): 16–18, 1993Google Scholar
- Adzick NS, Longaker MT. Scarless wound healing in the fetus: the role of the extracellular matrix. Progress in Clinical Biological Research 365: 177–192, 1991Google Scholar
- Alpar JJ. Endothelium protection using Healon®, serum or air in cataract extraction and intraocular lens implantation. Journal of Ocular Therapy and Surgery 3: 229–233, 1984Google Scholar
- Arshinoff S. The physical properties of ophthalmic viscoelastics in cataract surgery. Proceedings of the National Ophthalmic Speakers Program (NOSP), pp. 7–12, Montreal, Medicopea International Inc., 1992Google Scholar
- Assia El, Apple DJ, Lim ES, Morgan RC, Tsai JC. Removal of viscoelastic materials after experimental cataract surgery in vitro. Journal of Cataract and Refractory Surgery 18: 3–6, 1992Google Scholar
- Balazs EA, Denlinger JL. Viscosupplementation: a new concept in the treatment of Osteoarthritis. Journal of Rheumatology 20 (Suppl. 39): 3–9, 1993Google Scholar
- Balazs EA, Miller D, Stegmann R. Viscosurgery and the use of Na-hyaluronate in intraocular lens implantation. Presented at the International Congress and First Film Festival in Intraocular Implantation, Cannes, May 1979Google Scholar
- Balazs EA, Watson D, Duff IF, Roseman S. Hyaluronic acid in synovial fluid. I. Molecular parameters of hyaluronic acid in normal and arthritic human fluids. Arthritis and Rheumatism 10: 357–376, 1967Google Scholar
- Bernatchez SF, Camber O, Tabatabay C, Gurny R. Use of hyaluronic acid in ocular therapy. In Edman P (Ed) Biopharmaceutics of ocular drug delivery. CRC Press, Boca Raton, pp. 106–120, 1993aGoogle Scholar
- Bohnke M, Draeger J, Schneider M. Effects of Healon® and methylcellulose in protecting the cornea from mechanical trauma during surgery. Implant 4: 2–7, 1986Google Scholar
- Bothner H, Wik O. Rheology of intraocular solutions. In Rosen ES (Ed.) Viscoelastic materials: basic science and clinical applications. Vision and visual health care, Vol. 2, pp. 53–70, Pergamon Press, 1986Google Scholar
- Bragantini A, Cassini M, De Bastiani G, Perbellini A. Controlled single-blind trial of intra-articularly injected hyaluronic acid (Hyalgan®) in Osteoarthritis of the knee. Clinical Trials Journal 24: 333–340, 1987Google Scholar
- Brown T, Laurent UBG, Fraser JRE. Turnover of hyaluronan in synovial joints: elimination of labelled hyaluronan from the knee joint of the rabbit. Experimental Physiololgy 76: 125–143, 1991Google Scholar
- Carrabba M, Paresce E, Angelini M. The safety and efficacy of different dose schedules of hyaluronic acid in the treatment of painful Osteoarthritis of the knee with joint effusion. European Journal of Rheumatology and Inflammation, in press, 1993Google Scholar
- Carrabba M, Paresce E, Angelini M, Zamboni AM, Bragantini A, et al. The intra-articular treatment of Osteoarthritis of the knee. A comparative study between hyaluronic acid (Hyalgan®) and orgotein. European Journal of Rheumatology and Inflammation 12: 47–57, 1992Google Scholar
- Celleno L, Piperno S, Bracaglia R. Esperienze clinico-sperimentali suH’uso dell’acido ialuronico nei processi riparativi cutanei. Giornale Italiano di Dermatologia e Venereologia 120: 47–56, 1985Google Scholar
- Charteris DG, McConnell JMS, Adams AD. Effect of sodium hyaluronate on trabeculectomy filtration blebs. Journal of the College of Surgery in Edinburgh 36: 107–108, 1991Google Scholar
- Cherfan GM, Rich WJ, Wright G. Raised intraocular pressure and other problems with sodium hyaluronate and cataract surgery. Transactions of the Ophthalmological Society (UK) 103: 277–279, 1983Google Scholar
- Cortivo R, Govoni E, De Galateo A, Brun P, Abatangelo G. Hyaluronate reverses inhibition of proteoglycan synthesis by oxygen free-radicals in cultured embryonic cartilage. Abstract no. 46. European Journal of Cell Biology 49 (Suppl. 28): 18, 1989Google Scholar
- Creamer P, Sharif M, George E, Cushnaghan J, Dieppe P. Intra-articular hyaluronate reduces keratan sulphate levels in osteoarthritic (OA) synovial fluid. Abstract no. B93. Presented at the 56th Annual Scientific Meeting of the American College of Rheumatology, October 11–15, Atlanta, 1992Google Scholar
- Eisner G. Use of viscoelastic tools in ophthalmic surgery. In Eisner G (Ed.) Ophthalmic Viscosurgery, pp. 21–37, Medicopea International Inc., 1986Google Scholar
- Embriano PJ. Postoperative presssures after phacoemulsificaton: sodium hyaluronate vs. sodium chondroitin sulfate-sodium hyaluronate. Annals of Ophthalmology 21: 85–90, 1989Google Scholar
- Ferretti RG, Martini A, Morra B, Marchiori C, Tombolini A, et al. Hyaluronic acid in tympanic membrane perforation repair. Results of two multicenter, controlled clincal trials. Abstract. Presented at the 2nd European Congress of Oto-Rhino-Laryngology and Cervico Facial Surgery, Sorrento, Jun 6–10, 1992Google Scholar
- Frizziero L, Focherini MC, Govoni E. Hyaluronic acid versus methylprednisolone intra-articular treatment in knee Osteoarthritis: a comparative, integrated in vivo and ex vivo morphological assessment by arthroscopy and histopathology. Abstract. Revista Espanola de Reumatologia 20 (Suppl.1): 575, 1993Google Scholar
- Frizziero L, Zizzi F, Govoni E, Perbellini A. Destructive inflammatory Osteoarthritis of the knee joint. Microarthroscopic and ultra-structural study of the articular environment. Abstract. Revue du Rhumatisme 55: 830, 1988Google Scholar
- Fry LL. Postoperative intraocular pressure rises: a comparison of Healon, Amvisc and Viscoat. Journal of Cataract and Refractory Surgery 15: 415–420, 1989Google Scholar
- Ghosh P. The role of hyaluronic acid (hyaluronan) in health and disease — interactions with cartilage components and cells. European Journal of Rheumatology and Inflammaton, 1993, in pressGoogle Scholar
- Ghosh PK, Read R, Armstrong S, Wilson D, Marshall R, et al. The effects of intraarticular administration of hyaluronan in a model of early Osteoarthritis in sheep. I. Gait analysis and radiological and morphological studies. Seminars in Arthritis and Rheumatism 22 (Suppl. 1): 18–30, 1993PubMedCrossRefGoogle Scholar
- Hashimoto Y, et al. Multicenter clinical studies of ARTZ® (high molecular weight sodium hyaluronate) in the long term treatment of Osteoarthritis of the knee: including x-ray analysis. In Japanese. Yakuri to Chiryo 20: 347–360, 1992Google Scholar
- Härfstrand A, Molander N, Stenevi U, Apple D, Schenholm M, et al. Evidence of hyaluronic acid and hyaluronic acid binding sites on human corneal endothelium. Journal of Cataract and Refractory Surgery 18: 265–269, 1992Google Scholar
- Honma T, Maeda F, Kojima A, Ouchi F. Clinical efficacy of intraarticular injection of high molecular weight sodium hyaluronate (ARTZ®) in treatment of Osteoarthritis of the knee. In Japanese. Shinyaku to Chiryo 17: 451–466, 1989Google Scholar
- Hørslev-Petersen K, Bentsen KD, Engström-Laurent A, Junker P, Halberg P, et al. Serum amino terminal type III procollagen peptide and serum hyaluronan in rheumatoid arthritis: relation to clinical and serological parameters of inflammation during 8 and 24 months’ treatment with levamisole, penicillamine, or azathioprine. Annals of the Rheumatic Diseases 47: 116–126, 1988PubMedCrossRefGoogle Scholar
- Isdale AH, Hordon LD, Bird HA, Wright V. Intra-articular hyaluronate (Healon): a dose-ranging study in rheumatoid arthritis and Osteoarthritis. Journal of Drug Development 4: 93–99, 1991Google Scholar
- Jones AC, Patrick M, Doherty S, Doherty M. A double-blind trial of intra-articular hyaluronic acid (HA) versus intra-articular triam-cinolone hexacetonide (TH) in knee Osteoarthritis (OA). Abstract. Arthritis and Rheumatism 35 (Suppl.): S132, 1992Google Scholar
- Kammann J, Dornbach G, Vollenberg C, Hille P. Kontrollirte klinische Studie zweier viskoelastischer Substanzen. Fortschritte Ophthalmologie 88: 438–441, 1991Google Scholar
- Kawabata M, Igarashi M, Mikami R, Ninomiya S, Oda H, et al. Clinical evaluations of SLM-10 (sodium hyaluronate injection) in patients with Osteoarthritis of the knee. Yakuri to Chiryo 21: 257–283, 1993Google Scholar
- Kido H, Maeyama K, Tagawa T, Tomita T, Ito A, et al. Effect of high molecular weight sodium hyaluronate (SL-1010) on experimental Osteoarthritis induced by immobilization of rabbit knee joint. In Japanese. Japanese Journal of Pharmacology and Therapeutics 21 (Suppl. 2): 115–121, 1993Google Scholar
- Kikuchi T, Obara T, Yamaguchi T, Shimizu N, Iidaka T, et al. Effect of sodium hyaluronate with high molecular weight (SL-1010) on the experimental knee Osteoarthritis produced by transection of anterior cruciate ligament in beagle dogs. In Japanese. Pharmacometrics 44: 547–557, 1992Google Scholar
- Kikuchi T, Yamaguchi T, Sakakibara Y, Itoh H, Iwata H, et al. Therapeutic effect of high molecular weight sodium hyaluronate (SL-1010) on the experimental Osteoarthritis induced by rabbit knee immobilization. In Japanese. Japanese Pharmacology and Therapeutics 21 (Suppl. 2): 123–131, 1993Google Scholar
- Kondo T, Chichibu K, Usuki H, Matsuura T, Shichijo S, et al. Rapid assay of hyaluronic acid in serum. In Japanese. Rinsho Byori 39: 536–540, 1991Google Scholar
- Laurent UBG, Laurent TC. On the origin of hyaluronate in blood. Biochemistry International 2: 195–199, 1981Google Scholar
- Leardini G, Mattara L, Franceschini F, Perbellini A. Intra-articular treatment of knee Osteoarthritis. A comparative study between hyaluronic acid and 6-methylprednisolone acetate. Clinical and Experimental Rheumatology 9: 375–381, 1991Google Scholar
- Lequesne MG, Mery C, Samson M, Gerard P. Indexes of severity for Osteoarthritis of the hip and knee. Scandinavian Journal of Rheumatology (Suppl. 65): 85–89, 1987Google Scholar
- Longaker MT, Harrison MR, Crombleholme TM, Langer JC, Decker M, et al. Studies in fetal wound healing: I. A factor in fetal serum that stimulates deposition of hyaluronic acid. Journal of Pediatric Surgery 24: 789–792, 1989Google Scholar
- Madsen K, Schenholm M, Jahnke G, Tengblad A. Hyaluronate binding to intact corneas and cultured endothelial cells. Investigative Ophthalmology & Visual Science 30: 2132–2137, 1989Google Scholar
- Martini A, Cimino A, Drusian A, Ferretti RG, Magnolfi G, et al. The use of hyaluronic acid in tympanic membrane repair. Amulticenter clinical trial vs. placebo. Abstract. Presented at the Fifth International Symposium on Recent Advances in Otitis Media. Fort Lauderdale, May 20–24, 1991Google Scholar
- Martini A, Rubini R, Ferretti RG, Govoni E, Schiavinato A, et al. Comparative ototoxic potential of hyaluronic acid and methylcellulose. Acta Otolaryngologica (Stockholm): 112: 278–283, 1992Google Scholar
- Masuda K, Sawa M, Fukado Y, Sakimoto T. Phase II clinical study of sodium hyaluronate in penetrating keratoplasty. In Japanese. Yakuri to Chiryo 19: 365–375, 1991Google Scholar
- Mensitieri M, Ambrosio L, Iannace S, Perbellini A, Nicolais L. Viscoelastic evaluation of different knee Osteoarthritis therapies. In Bonfield (Ed) Journal of Material Science: Materials in Medicine, in press, 1993Google Scholar
- Miura T, Tanba S, Yoshizawa H, Matsui N, Nagaya I. High molecular weight Na-hyaluronate intra-articular injection for patients with rheumatoid arthritis combined with Osteoarthritis of the knee joint. In Japanese. Igaku to Yakugaku 29: 1061–1071, 1993Google Scholar
- Miyauchi S, Iwata S. Biochemical studies on the use of sodium hyaluronate in the anterior eye segment. IV. The protective efficacy of the corneal endothelium. Current Eye Research 3: 1063–1067, 1984Google Scholar
- Miyauchi S, Iwata S. Evaluations on the usefulness of viscous agents in anterior segment surgery. II. Effect on intraocular pressure and clearance from the anterior chamber. Journal of Ocular Pharmacology 5: 221–232, 1989Google Scholar
- Molander N, Lindquist U, Lind M-L, Stenevi U, Ehinger B. Influence of anterior segment trauma on endogenous hyaluronan in the rabbit cornea and aqueous. European Journal of Implant and Refractory Surgery 5: 121–127, 1993bGoogle Scholar
- Morisawa K, Takagi K. Clinical evaluation of SLM-10 (high molecular weight sodium hyaluronate) on periarthritis of the shoulder. In Japanese. Japanese Pharmacology and Therapeutics 21 (Suppl. 2): 355–365, 1993Google Scholar
- Namiki O, Toyoshima H, Morisaki N. Therapeutic effect of intra-articular injection of high molecular weight hyaluronic acid on Osteoarthritis of the knee. International Journal of Clinical Pharmacology, Therapy and Toxicology 20: 501–507, 1982Google Scholar
- Niethard FU, Graf J, Neusel E, Schneider E. Clinical efficacy of hyaluronic acid in Osteoarthritis. Abstract. Revista Espanola de Reumatologia 20 (Suppl. 1): 576, 1993Google Scholar
- Obara T, Yamaguchi T, Moriya Y, Namba K. Tissue distribution of fluoroscein-labeled sodium hyaluronate in experimentally-induced Osteoarthritis. In Japanese. Japanese Pharmacology and Therapeutics 21 (Suppl. 2): 193–200, 1993Google Scholar
- Ono K, Nakahara H, Yonenobu K, Ochi T, Hongo I, et al. Study of the effect of intra-articular injection of high molecular weight sodium hyaluronate (SLM-10) on Osteoarthritis of the knee joint. In Japanese. Japanese Pharmacology and Therapeutics 21 (Suppl. 2): 333–354, 1993aGoogle Scholar
- Ono K, Hirasawa Y, Matsui N, Moriya H. A study of the effect of intra-articular long term injection of high molecular weight sodium hyaluronate (SLM-10) on Osteoarthritis of the knee joint. In Japanese. Japanese Pharmacology and Therapeutics 21 (Suppl. 2): 409–424, 1993bGoogle Scholar
- Partsch G, Schwarzer Ch, Neumüller J, Dunky A, Petera P, et al. Modulation of the migration and Chemotaxis of PMN cells by hyaluronic acid. In German. Zeitschrift für Rheumatologie 48: 123–128, 1989Google Scholar
- Pasquali Ronchetti L, Frizziero L, Focherini MC, Guerra D. The synovial membrane after treatment with hyaluronic acid and 6-methylprednisolone. Abstract. Revista Espanola de Reumatologia 20 (Suppl. 1): 574, 1993Google Scholar
- Passarini B, Tosti A, Fanti PA, Varotti C. Effetto dell’acido ialuronico sul processo riparativo delie ulcere trofiche. Giornale Italiano di Dermatologia e Venereologia 117: 27–30, 1982Google Scholar
- Pelletier J-P, Martel-Pelletier J. The pathophysiology of Osteoarthritis and the implication of the use of hyaluronan and hylan as therapeutic agents in viscosupplementation. Journal of Rheumatology 20 (Suppl. 39): 19–24, 1993Google Scholar
- Peluso GF, Perbellini A, Tajana GF. The effect of high and low molecular weight hyaluronic acid on mitogen-induced lymphocyte proliferation. Current Therapeutic Research 47: 437–443, 1990Google Scholar
- Percival SPB. Sodium hyaluronate in perspective: experiences from a four-year clinical trial. Transactions of the Ophthalmological Society (UK) 104: 616–620, 1985Google Scholar
- Pietrogrande V, Melanotte PL, D’Agnolo B, Ulivi M, Benigni GA, et al. Hyaluronic acid versus methylprednisolone intra-articularly injected for treatment of Osteoarthritis of the knee. Current Therapeutic Research 50: 691–701, 1991Google Scholar
- Polack FM, Demong T, Santaella H. Sodium hyaluronate (Healon®) in keratoplasty and IOL implantation. Ophthalmology 89: 425–431, 1982Google Scholar
- Pop M. The clinical performance of viscoelastics during phacoemulsification. Proceedings of the National Ophthalmic Speakers Program (NOSP), Montreal, pp. 13–14, Medicopea International Inc, 1992Google Scholar
- Punzi L, Schiavon F, Ramonda R, Malatesta V, Gambari P, et al. Intra-articular hyaluronic acid in the treatment of inflammatory and noninflammatory knee effusions. Current Therapeutic Research 43: 643–647, 1988Google Scholar
- Rafuse PE, Nichols BD. Effects of Healon vs. Viscoat on endothelial cell count and morphology and phacoemulsification and posterior chamber lens implantation. Canadian Journal of Ophthalmology 27: 125–129, 1992Google Scholar
- Ravalico G, Agolini G, Ammirati M, Bellavitis A. Use of viscoelastic substances of different molecular weight in IOL implantation in-the-bag. Italian Journal of Ophthalmology 4: 221–226, 1990Google Scholar
- Retanda G. Acido ialuronico nei processi di riparazione délie ulcere cutanee. Giornale Italiano di Dermatologia e Venereologia 120: 71–75, 1985Google Scholar
- Roper-Hall MJ. Viscoelastic materials in the surgery of ocular trauma. Transactions of the Ophthalmololgical Society (UK) 103: 274–276, 1983Google Scholar
- Russell IJ, Michalek JE, Lawrence VA, Lessard JA, Briggs BT et al. A randomized, placebo (PI) and no-intervention (NI) controlled, trial of intra-articular (IA) 1% sodium hyaluronate in the treatment of knee Osteoarthritis. Abstract. Arthritis and Rheumatism 35 (Suppl): S132, 1992Google Scholar
- Sakimoto T, Tazawa Y, Fukamichi Y, Usui M, Masuda K. A clinical evaluation of 1% SL-1010 intraocular injection in penetrating keratoplasty. In Japanese. Yakuri to Chiryo 19: 397–419, 1991Google Scholar
- Sawa M, Murao M, Yanagi M, Shiratori K, Morita H. Study on safety of sodium hyaluronate by injection in the anterior chamber. In Japanese. Nippon Ganka Gakkai Zasshi 97: 448–454, 1993Google Scholar
- Shibata S. Clinical use of sodium hyaluronate (ARTZ®) in treatment of Osteoarthritis of the knee. Shinyaku to Rinsho 42: 126–130, 1993Google Scholar
- Smith KD, Burt WL. Fluorescent viscoelastic enhancement. Journal of Cataract and Refractory Surgery 18: 572–576, 1992Google Scholar
- Stegmann R, Miller D. Extracapsular cataract extraction with hyaluronate sodium. Annals of Ophthalmolgy 813–815, 1982Google Scholar
- Stenkula S, Ivert L, Gislason I, Tornquist R, Weijdegard L. The use of sodium-hyaluronate (Healon) in the treatment of retinal detachment. Ophthalmic Surgery 435–437, 1981Google Scholar
- Subramanian N, Bunyaratavej N, Chan KM. The use of hyaluronic acid (Hyalgan) in the treatment of OA of the knee: results of a multicentre, randomised, double-blind (masked observer), placebo-controlled trial. Presented at the 11th Congress of the ASEAN Orthopaedic Association, Malaysia, November 20–23, 1991Google Scholar
- Suzu F, Hirasawa Y. Long-term use of ARTZ (high molecular weight sodium hyaluronate) in treatment of Osteoarthritis of the knee. In Japanese. Shinyaku to Chiryo 18: 225–230, 1990Google Scholar
- Tsuboi I, Kotera N, Shichijo S, Namba K, Suzuki K, et al. Effect of high molecular weight sodium hyaluronate (SL-1010) on human neutrophil function. In Japanese. Japanese Journal of Inflammation 3: 55–61, 1993Google Scholar
- Tsukanishi S, Nobuhara K. Clinical effect of SLM-10 (high molecular weight sodium hyaluronate) in patients with periarthritis of the shoulder. In Japanese. Japanese Pharmacology and Therapeutics 21 (Suppl. 21): 367–378, 1993Google Scholar
- Ueo T, Okumura H, Shimizu K, Kasai R. Changes of synovial fluid properties after intraarticular injection of high molecular weight hyaluronate in patients with rheumatoid arthritis. In Japanese. Japanese Journal of Inflammation 11: 169–173, 1991Google Scholar
- Usui M, Fukamichi YY, Tobari I, Shimizu K, Tanaka S. A phase III clinical comparative trial of sodium hyaluronate (SL-1010) in intraocular lens implantation. In Japanese. Yakuri to Chiryo 19: 377–396, 1991Google Scholar
- Vannini AM, Ferrari MP, Dalla Valle I, Magnolfi G, et al. The biological rationale underlying the therapeutic effectiveness of exogenous hyaluronic acid and low-frequency pulsed electromagnetic fields in pressure ulcer medical treatment. In Abatangelo & Davidson (Eds) Cutaneous Development, Aging and Repair. Fidia Research Series 18, pp. 81–95, Liviana Press, Padova, 1989Google Scholar
- Vatne HO, Syrdalen P. The use of sodium hyaluronate (Healon) in the treatment of complicated cases of retinal detachment. Acta Ophthalmologica 169–172, 1986Google Scholar
- Worrall JG, Bayliss MT, Edwards JCW. Morphological localization of hyaluronan in normal and diseased synovium. Journal of Rheumatology 18: 1466–1472, 1992Google Scholar
- Yamada T, Jikihara S, Funahashi M. Ocular response to viscous substances in rabbits. In Japanese. Folia Ophthalmologica 40: 269–274, 1989Google Scholar
- Yamamoto R, Tabata S, Mikasa M, Takagishi K, Ogawa N. Doserange finding study of SLM-10 (sodium hyaluronate injection) in patients with periarthritis scapulohumeralis. In Japanese. Japanese Pharmacology and Therapeutics 21 (Suppl. 2): 265–286, 1993aGoogle Scholar
- Yamamoto R, Tabata S, Mikasa M, Takagishi K, Ogawa N. Clinical trial of SLM-10 (sodium hyaluronate injection) compared with ARTZ® in patients with periarthritis scapulohumeralis. In Japanese. Yakuri to Chiryo 21: 285–307, 1993bGoogle Scholar